Vyome (NASDAQ:HIND – Get Free Report) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Thursday.
Several other equities analysts have also recently issued reports on the company. Maxim Group reissued a “buy” rating and issued a $15.00 price objective on shares of Vyome in a report on Thursday, October 2nd. Citigroup raised Vyome to a “buy” rating in a report on Thursday, October 2nd. Two investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $15.00.
Check Out Our Latest Analysis on Vyome
Vyome Trading Down 5.5%
About Vyome
ReShape Lifesciences Inc, a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract.
Read More
- Five stocks we like better than Vyome
- What is the S&P 500 and How It is Distinct from Other Indexes
- Lowe’s vs. Home Depot: Which Benefits More From Lower Rates?
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- These 5 Beaten-Down Tech Stocks Could Catch Fire Next
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Falcon Flex Drives Growth as CrowdStrike Bets on AI Security
Receive News & Ratings for Vyome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vyome and related companies with MarketBeat.com's FREE daily email newsletter.